DOAJ Open Access 2022

Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:

Adeeb A. Bulkhi, MD, MSc Ahmad A. Mirza, MBBS, MSc Abdullah J. Aburiziza, MD, ABP Osama A. Marglani, MD, FRCSC

Abstrak

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.

Topik & Kata Kunci

Immunologic diseases. Allergy

Penulis (4)

Adeeb A. Bulkhi, MD, MSc

Ahmad A. Mirza, MBBS, MSc

Abdullah J. Aburiziza, MD, ABP

Osama A. Marglani, MD, FRCSC

Format Sitasi

APA MLA BibTeX

MSc, A.A.B.M., MSc, A.A.M.M., ABP, A.J.A.M., FRCSC, O.A.M.M. (2022). Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:. https://doi.org/10.1016/j.waojou.2022.100638

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.1016/j.waojou.2022.100638

Informasi Jurnal

Tahun Terbit: 2022
Sumber Database: DOAJ
DOI: 10.1016/j.waojou.2022.100638
Akses: Open Access ✓